Milestone Scientific Inc. (MLSS), a biomedical technology company, announced financial results for the fourth quarter reflecting a narrower net loss. In addition, the company provided revenue guidance for the full year 2026.
Following the news, MLSS is up 5.56% at $0.30 in the pre-market.
Company Profile
Milestone designs, develops, and commercialises diagnostic and therapeutic injection technologies and devices for medical and dental use.
Their proprietary DPS Dynamic Pressure Sensing Technology is the platform for developing next-generation devices.
Milestone offers,
- Wand, a single-use disposable handpiece device for dental procedures that require local anaesthetic under its CompuDent and STA Single Tooth Anaesthesia System. -CompuFlo is a computer-controlled drug delivery system for the painless delivery of drugs, anaesthetics, and other medicaments.-Disposable injection handpiece for the tactile control during the injection. -CompuMed for use in various medical procedures performed in plastic, hair restoration, and colorectal surgery.
Q4 Results
For the fourth quarter, net loss narrowed to $1.1 million from $2.0 million in the prior year.
Net revenue increased to $2.04 million from $2.0 million, respectively, an increase of 2.2% or $45,00 from the year-ago period.
FY25 Results
For the full year 2025, Net loss expanded to $5.72 million, or $ 0.07 per share, from $4.71 million, or $0.06 per share.
Total revenue improved 4% to $8.97 million from $8.63 million in the prior year.
As of December 31, 2025, the company had cash of $ 1.11 million.
2026 Guidance
Looking ahead to 2026, the firm expects total revenue to be in the range of $9.8 million to $10.2 million, an improvement of approximately 9% to 14% from 2025.
Within that range, CompuFlo revenue is expected to be $5 million to $6 million, representing an approximately 400% increase over 2025, according to the firm.
"Our objective is clear: position the Company to achieve cash flow breakeven in early 2027 and create long-term shareholder value." Said Eric Hines, Chief Executive Officer of Milestone Scientific.
MLSS has traded between 0.22 and $1.11 in the last year. The stock closed Tuesday's trade at $0.28, down 5.26.
For More Such Biotech and Pharmaceutical News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.